The use of almost every antibiotic increases the chances of Clostridioides difficile infection, and that includes the drugs that are used to treat C diff, a study states.
When it comes to what circumstances help breed Clostridioides difficile infection (CDI), there are some that could be called the usual suspects. They include increased age, hospitalization, use of proton pump inhibitors, and use of antibiotics, according to a recent study out of Pakistan. That study, published in Cureus,1 looked at data from 200 patients diagnosed with
C difficile–associated diarrhea (CDAD) at a tertiary care hospital in Pakistan between June 2020 and March 2021, along with 200 patients without CDAD in a control group.
“Identifying and addressing the risk factors associated with CDI will help [reduce] the incidence of infection and associated complications,” the authors, led by Aarzoo Gupta of Vardhman Mahavir Medical College and Safdarjung Hospital in Faridabad, India, wrote.
The study included detailed histories of patients’ use of treatments (antibiotics, proton pump inhibitors, and histamine 2 receptor antagonists), previous CDI diagnoses, and hospitalization in the past 30 days. Investigators also noted patients’ body mass index (BMI) and comorbidities including diabetes, chronic kidney disease (CKD), hypertension, and malignancy.
In the case group, 31 patients were older than 65 (15.5%), compared with 16 (8%) in the control group (OR [odds ratio], 2.10 [1.11-3.99]; P = .02). “This age group is not only termed as a risk factor for CDI but such patients also demonstrate poor prognosis, leading to increased clinical severity and death rates,” the authors wrote.
Patients with CDI also had significantly higher hospitalization (25.5% vs 6%; OR, 5.36 [2.75-10.42]; P < .0001), use of proton pump inhibitors in past 30 days (23.0% vs 10.5%; OR, 2.54 [1.45-4.45]; P = .001), and use of antibiotics in the past 30 days (36.0% vs 10.5%; OR, 4.76 [2.80-8.19]; P < .0001).
“Studies have suggested that almost every antibiotic results in an increased chance of developing CDI,” the authors wrote. “This also includes the drugs that are used to treat CDI, namely metronidazole and vancomycin.”
Other risk factors included a BMI above 25 kg/m2 (31% vs 21%; OR, 1.69 [1.07-2.65]; P = .02), diabetes (27% vs 16%; OR, 1.94 [1.18-2.17]; P = .008), CKD (19% vs 9.5%; OR, 2.23 [1.23-4.03]; P = .007), and malignancy (6% vs 2%; OR, 3.12 [0.99-9.86]; P = .05).
“Given the findings [above], our study suggests that the use of acid-suppressive agents should be carefully considered, and the over-the-counter availability of these agents should be discouraged,” the authors wrote. “This would help the doctors to keep a check in order to avoid overdose. Moreover, hygiene practices, such as hand washing practices, sterilizing used [equipment] at the hospital, using clean medical devices, etc, should be adopted to avoid infection risk. Maximum management of antibiotic intake should also be taken into consideration.”
CDI is the leading cause of health care–associated infections, causing about a half million infections and $1 billion in health care costs each year. Although CDI is often associated with health care settings, a recent study by investigators at the University of Houston found that the bacterium is prevalent in a variety of settings, including on 45% of shoe soles.2 Healthy people can carry CDI without illness or symptoms.
This article originally appeared in Contagion®3
References:
Managing Multimorbidity and Polypharmacy in HIV: Insights From Michelle S. Cespedes, MD, MS
November 20th 2024Michelle S. Cespedes, MD, MS, discusses the challenges of managing multimorbidity and polypharmacy in HIV treatment, emphasizing patient education, evolving guidelines, and real-world insights from the REPRIEVE study.
Longhorn Vaccines and Diagnostics to Showcase Breakthrough Vaccine Data at IDWeek 2024
November 19th 2024Longhorn Vaccines and Diagnostics revealed promising data on universal influenza vaccine LHNVD-110 and AMR sepsis vaccine LHNVD-303 at IDWeek 2024, addressing critical global health challenges.
Infection Intel: Revolutionizing Ultrasound Probe Disinfection With Germitec's Chronos
November 19th 2024Learn how Germitec’s Chronos uses patented UV-C technology for high-level disinfection of ultrasound probes in 90 seconds, enhancing infection control, patient safety, and environmental sustainability.
CDC HICPAC Considers New Airborne Pathogen Guidelines Amid Growing Concerns
November 18th 2024The CDC HICPAC discussed updates to airborne pathogen guidelines, emphasizing the need for masks in health care. Despite risks, the committee resisted universal masking, highlighting other mitigation strategies
The Importance of Hand Hygiene in Clostridioides difficile Reduction
November 18th 2024Clostridioides difficile infections burden US healthcare. Electronic Hand Hygiene Monitoring (EHHMS) systems remind for soap and water. This study evaluates EHHMS effectiveness by comparing C difficile cases in 10 hospitals with CMS data, linking EHHMS use to reduced cases.